Table: Anges -Q1 group results
May 10 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2023 Mar 31, 2022 Dec 31, 2023
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 16 mln 15 mln 190 mln
(+7.9 pct) (+33.3 pct) (+183.3 pct)
Operating loss 3.04 loss 3.54 loss 15.50
Recurring loss 2.90 loss 2.93 loss 9.90
Net loss 2.91 loss 2.94 loss 10.00
EPS loss 15.91 yen loss 19.20 yen loss 53.71 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001